BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/19/2026 7:07:29 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-11-25 03:25 |
|
Peer-Review Started |
|
2025-11-25 03:26 |
|
First Decision by Editorial Office Director |
|
2025-12-16 09:59 |
|
Return for Revision |
|
2025-12-16 09:59 |
|
Revised |
|
2025-12-29 02:10 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-09 02:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-09 09:55 |
|
Articles in Press |
|
2026-01-09 09:55 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-28 07:59 |
|
Publish the Manuscript Online |
|
2026-03-19 07:07 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
From clinical efficacy to population health: Implementing vonoprazan-amoxicillin dual therapy for Helicobacter pylori control
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Qing Chen, Kang-Ning Li and Tian-Qi Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Medical and Health Appropriate Technology Development and Promotion Project of the Health Commission of Guangxi Zhuang Autonomous Region |
No. S2023034 |
|
| Corresponding Author |
Tian-Qi Liu, Consultant, MD, PhD, Professor, Department of General Surgery, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, No. 85 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. ljrqt@126.com |
| Key Words |
Helicobacter pylori; Vonoprazan; Amoxicillin; Dual therapy; Eradication treatment; Public health; Pharmacoeconomics; Antibiotic resistance |
| Core Tip |
This editorial highlights vonoprazan-amoxicillin dual therapy, particularly the 0.5 g four-times-daily regimen, as a highly effective, safe, and well-tolerated strategy for Helicobacter pylori eradication, based on a recent large-scale regional trial. Its exceptional cost-effectiveness, high patient compliance, and dosing simplicity position it as a transformative candidate for large-scale public health interventions that aimed at reducing the burden of Helicobacter pylori-associated diseases, including gastric cancer. Successful implementation, however, necessitates addressing challenges such as antimicrobial resistance surveillance and ensuring equitable access to healthcare systems. |
| Publish Date |
2026-03-19 07:07 |
| Citation |
Chen Q, Li KN, Liu TQ. From clinical efficacy to population health: Implementing vonoprazan-amoxicillin dual therapy for Helicobacter pylori control. World J Gastroenterol 2026; 32(12): 116953 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i12/116953.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i12.116953 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
